Yesterday, the UK's largest Pharmaceutical company, GSK announced pans to split in two after spinning off its consumer product unit into a joint venture with US rival Pfizer. Shares in GSK closed 3.8 per cent higher in London while Pfizer shares were down 1.01% in NY. www.ft.com/content/3...e9-9d01-cd4d49afbbe3 The US drug makers' stock remains vulnerable to wider equity market weakness and $42.00 is both a technical and psychological support level. Further downside support is the 38.2 Fib level at 41.70 and the 50.00 level at 40.35. The downtrend could be broken with a breach and hold of 43.53 (23.6 Fib) and 44.30 at the 20 SMA.